These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 29423538)
1. Genomic analysis of synchronous intracranial meningiomas with different histological grades. Chowdhury T; Yoo Y; Seo Y; Dho YS; Kim S; Choi A; Choi M; Park SH; Park CK; Lee SH; Lee JY J Neurooncol; 2018 May; 138(1):41-48. PubMed ID: 29423538 [TBL] [Abstract][Full Text] [Related]
2. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation. Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203 [TBL] [Abstract][Full Text] [Related]
3. Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions? Sayagués JM; Tabernero MD; Maíllo A; Espinosa A; Rasillo A; Díaz P; Ciudad J; López A; Merino M; Gonçalves JM; Santos-Briz A; Morales F; Orfao A J Mol Diagn; 2004 Nov; 6(4):316-25. PubMed ID: 15507670 [TBL] [Abstract][Full Text] [Related]
4. Comparative genomic hybridization analysis of genomic alterations in benign, atypical and anaplastic meningiomas. Arslantas A; Artan S; Oner U; Durmaz R; Müslümanoğlu H; Atasoy MA; Başaran N; Tel E Acta Neurol Belg; 2002 Jun; 102(2):53-62. PubMed ID: 12161900 [TBL] [Abstract][Full Text] [Related]
5. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924 [TBL] [Abstract][Full Text] [Related]
6. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence. Bie L; Zhao G; Ju Y; Zhang B Cancer Genet; 2011 Oct; 204(10):536-40. PubMed ID: 22137483 [TBL] [Abstract][Full Text] [Related]
7. Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. Al-Mefty O; Kadri PA; Pravdenkova S; Sawyer JR; Stangeby C; Husain M J Neurosurg; 2004 Aug; 101(2):210-8. PubMed ID: 15309910 [TBL] [Abstract][Full Text] [Related]
8. Masked hypodiploidy in anaplastic meningiomas by duplication of the original clone found in atypical meningiomas: illustration of the evolution of genetic alterations. Ely EE; Guzman MA; Calvey LS; Batanian JR Neuropathology; 2014 Aug; 34(4):353-9. PubMed ID: 24612240 [TBL] [Abstract][Full Text] [Related]
9. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Wrobel G; Roerig P; Kokocinski F; Neben K; Hahn M; Reifenberger G; Lichter P Int J Cancer; 2005 Mar; 114(2):249-56. PubMed ID: 15540215 [TBL] [Abstract][Full Text] [Related]
11. Genomic profile of human meningioma cell lines. Mei Y; Bi WL; Greenwald NF; Agar NY; Beroukhim R; Dunn GP; Dunn IF PLoS One; 2017; 12(5):e0178322. PubMed ID: 28552950 [TBL] [Abstract][Full Text] [Related]
12. High resolution genomic profiling and classical cytogenetics in a group of benign and atypical meningiomas. Holland H; Mocker K; Ahnert P; Kirsten H; Hantmann H; Koschny R; Bauer M; Schober R; Scholz M; Meixensberger J; Krupp W Cancer Genet; 2011 Oct; 204(10):541-9. PubMed ID: 22137484 [TBL] [Abstract][Full Text] [Related]
13. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Lusis EA; Watson MA; Chicoine MR; Lyman M; Roerig P; Reifenberger G; Gutmann DH; Perry A Cancer Res; 2005 Aug; 65(16):7121-6. PubMed ID: 16103061 [TBL] [Abstract][Full Text] [Related]
15. Clinical potential of meningioma genomic insights: a practical review for neurosurgeons. Karsy M; Azab MA; Abou-Al-Shaar H; Guan J; Eli I; Jensen RL; Ormond DR Neurosurg Focus; 2018 Jun; 44(6):E10. PubMed ID: 29852774 [TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Rempel SA; Schwechheimer K; Davis RL; Cavenee WK; Rosenblum ML Cancer Res; 1993 May; 53(10 Suppl):2386-92. PubMed ID: 8485725 [TBL] [Abstract][Full Text] [Related]
18. Expression and gene doses changes of the p53-regulator PPM1D in meningiomas: a role in meningioma progression? Fukami S; Riemenschneider MJ; Kohno M; Steiger HJ Brain Tumor Pathol; 2016 Jul; 33(3):191-9. PubMed ID: 26942600 [TBL] [Abstract][Full Text] [Related]
19. Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in situ hybridization. Ishino S; Hashimoto N; Fushiki S; Date K; Mori T; Fujimoto M; Nakagawa Y; Ueda S; Abe T; Inazawa J Cancer; 1998 Jul; 83(2):360-6. PubMed ID: 9669820 [TBL] [Abstract][Full Text] [Related]
20. Histological classification and molecular genetics of meningiomas. Riemenschneider MJ; Perry A; Reifenberger G Lancet Neurol; 2006 Dec; 5(12):1045-54. PubMed ID: 17110285 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]